Research programme: immunoproteasome inhibitors - Onyx Pharmaceuticals

Drug Profile

Research programme: immunoproteasome inhibitors - Onyx Pharmaceuticals

Alternative Names: ONX 0914; ONYX 0914; PR-957

Latest Information Update: 24 Oct 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Proteolix
  • Developer Onyx Pharmaceuticals; Proteolix
  • Class Epoxy compounds; Ketones; Peptides; Small molecules
  • Mechanism of Action Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Autoimmune disorders
  • No development reported Haematological malignancies

Most Recent Events

  • 01 Oct 2013 Onyx Pharmaceuticals has been acquired by Amgen
  • 14 Mar 2012 Preclinical development is ongoing for Autoimmune disorders in USA
  • 14 Mar 2012 No development reported - Preclinical for Haematological malignancies in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top